Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Aug 25, 2016
Neuren expands Phase 2 Rett syndrome pediatric trial
Jul 26, 2016
Appendix 4C - quarterly
Jun 24, 2016
Neuren presents at Rettsyndrome.org 2016 Research Symposium
Jun 22, 2016
Grant of new patent for Autism Spectrum Disorders
May 31, 2016
Results of Meeting
May 31, 2016
Chairman's Address to Shareholders
May 16, 2016
Change of Director's Interest Notice
May 13, 2016
Presentation at 6th Annual TBI Conference, Washington DC
May 02, 2016
Notice of Annual General Meeting/Proxy Form
Apr 29, 2016
Appendix 4C - quarterly
Previous
1
2
3
4
Next
